Similarly, Mackin et al. found decreased CSF αSyn in AD patients with hallucinations and, when adjusted for Tau concentrations, with longitudinal decline in performance of executive function, i. e. two clinical symptoms often observed in DLB, compared to the AD patients without these symptoms. The gene discussed is MAPT; the disease is Alzheimer disease.